UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics

Cell research, 2015-06, Vol.25 (6), p.707-725

2015

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia

Journal of clinical oncology, 2012-12, Vol.30 (36), p.4515-4523

2012

Link zum Volltext

Verfügbarkeit prüfen

Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk Patients

Journal of clinical oncology, 2013-06, Vol.31 (17), p.2086-2093

2013

Link zum Volltext

Verfügbarkeit prüfen

IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

Journal of clinical oncology, 2010-05, Vol.28 (14), p.2348-2355

2010

Link zum Volltext

Verfügbarkeit prüfen

TET2 Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

Journal of clinical oncology, 2011-04, Vol.29 (10), p.1373-1381

2011

Link zum Volltext

Verfügbarkeit prüfen

Age-Related Prognostic Impact of Different Types of DNMT3A Mutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia

Journal of clinical oncology, 2012-03, Vol.30 (7), p.742-750

2012

Link zum Volltext

Verfügbarkeit prüfen

MicroRNA Expression in Cytogenetically Normal Acute Myeloid Leukemia

The New England journal of medicine, 2008-05, Vol.358 (18), p.1919-1928

2008

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Significance of, and Gene and MicroRNA Expression Signatures Associated With, CEBPA Mutations in Cytogenetically Normal Acute Myeloid Leukemia With High-Risk Molecular Features: A Cancer and Leukemia Group B Study

Journal of clinical oncology, 2008-11, Vol.26 (31), p.5078-5087

2008

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Significance of Expression of a Single MicroRNA, miR-181a, in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

Journal of clinical oncology, 2010-12, Vol.28 (36), p.5257-5264

2010

Link zum Volltext

Verfügbarkeit prüfen

Wilms’ Tumor 1 Gene Mutations Independently Predict Poor Outcome in Adults With Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

Journal of clinical oncology, 2008-10, Vol.26 (28), p.4595-4602

2008

Link zum Volltext

Verfügbarkeit prüfen

Patients With Acute Myeloid Leukemia and RAS Mutations Benefit Most From Postremission High-Dose Cytarabine: A Cancer and Leukemia Group B Study

Journal of clinical oncology, 2008-10, Vol.26 (28), p.4603-4609

2008

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Importance of MN1 Transcript Levels, and Biologic Insights From MN1-Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

Journal of clinical oncology, 2009-07, Vol.27 (19), p.3198-3204

2009

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Factors and Outcome of Core Binding Factor Acute Myeloid Leukemia Patients With t(8;21) Differ From Those of Patients With inv(16): A Cancer and Leukemia Group B Study

Journal of clinical oncology, 2005-08, Vol.23 (24), p.5705-5717

2005

Link zum Volltext

Verfügbarkeit prüfen

High Expression Levels of the ETS-Related Gene, ERG, Predict Adverse Outcome and Improve Molecular Risk-Based Classification of Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

Journal of clinical oncology, 2007-08, Vol.25 (22), p.3337-3343

2007

Link zum Volltext

Verfügbarkeit prüfen

Inpatient computer-based standing orders vs physician reminders to increase influenza and pneumococcal vaccination rates: a randomized trial

JAMA : the journal of the American Medical Association, 2004-11, Vol.292 (19), p.2366

2004

Link zum Volltext

Verfügbarkeit prüfen

Reply to K. Orendi et al

Journal of clinical oncology, 2013-06, Vol.31 (18), p.2361-2362

2013

Link zum Volltext

Verfügbarkeit prüfen

Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia

Proceedings of the National Academy of Sciences - PNAS, 2012-04, Vol.109 (17), p.6668-6673

2012

Link zum Volltext

Verfügbarkeit prüfen

Phase I Study of Oblimersen Sodium, an Antisense to Bcl-2, in Untreated Older Patients With Acute Myeloid Leukemia: Pharmacokinetics, Pharmacodynamics, and Clinical Activity

Journal of clinical oncology, 2005-05, Vol.23 (15), p.3404-3411

2005

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 97

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(92)
Mit Volltextzugriff
(94)

Publikationsform

Artikel
(97)

Sprache

Englisch
(97)
Japanisch
(12)

Erscheinungsjahr

n.n

Thema

Humans
(57)
Science & Technology
(56)
Life Sciences & Biomedicine
(55)
Female
(47)
Middle Aged
(46)
Male
(43)
Biological And Medical Sciences
(39)
Medical Sciences
(38)
Adult
(36)
Leukemia, Myeloid, Acute - Genetics
(35)
Aged
(32)
Hematologic And Hematopoietic Diseases
(32)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(32)
Oncology
(29)
Aged, 80 And Over
(25)
Prognosis
(24)
Hematology
(21)
Tumors
(21)
Adolescent
(20)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(19)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia

Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk Patients

Identification of a 24-Gene Prognostic Signature That Improves the European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: An International Collaborative Study

IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia

RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures

TET2 Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

Age-Related Prognostic Impact of Different Types of DNMT3A Mutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia

An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia

Favorable Prognostic Impact of NPM1 Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study

MicroRNA Expression in Cytogenetically Normal Acute Myeloid Leukemia

Prognostic Significance of, and Gene and MicroRNA Expression Signatures Associated With, CEBPA Mutations in Cytogenetically Normal Acute Myeloid Leukemia With High-Risk Molecular Features: A Cancer and Leukemia Group B Study

Prognostic Significance of Expression of a Single MicroRNA, miR-181a, in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

Wilms’ Tumor 1 Gene Mutations Independently Predict Poor Outcome in Adults With Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

Patients With Acute Myeloid Leukemia and RAS Mutations Benefit Most From Postremission High-Dose Cytarabine: A Cancer and Leukemia Group B Study

Prognostic Importance of MN1 Transcript Levels, and Biologic Insights From MN1-Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

Prognostic Factors and Outcome of Core Binding Factor Acute Myeloid Leukemia Patients With t(8;21) Differ From Those of Patients With inv(16): A Cancer and Leukemia Group B Study

High Expression Levels of the ETS-Related Gene, ERG, Predict Adverse Outcome and Improve Molecular Risk-Based Classification of Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

Inpatient computer-based standing orders vs physician reminders to increase influenza and pneumococcal vaccination rates: a randomized trial

Reply to K. Orendi et al

Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia

Phase I Study of Oblimersen Sodium, an Antisense to Bcl-2, in Untreated Older Patients With Acute Myeloid Leukemia: Pharmacokinetics, Pharmacodynamics, and Clinical Activity

The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy

Suchergebnisse filtern